PT Indofarma Tbk's total inventories for the quarter that ended in Dec. 2025 was Rp65,552 Mil. PT Indofarma Tbk's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Dec. 2025 was Rp51,747 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. PT Indofarma Tbk's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was Rp-384.11.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
PT Indofarma Tbk's Days Inventory for the
three
months ended in Dec. 2025 was 185.48.
Inventory Turnover measures how fast the company turns over its inventory within a year.
PT Indofarma Tbk's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.49.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PT Indofarma Tbk's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 2.90.
PT Indofarma Tbk (ISX:INAF) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
PT Indofarma Tbk's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PT Indofarma Tbk's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
PT Indofarma Tbk Total Inventories Related Terms
PT Indofarma Tbk Total Inventories Historical Data
* Premium members only.
The historical data trend for PT Indofarma Tbk's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of Rp65,552 Mil mean?
PT Indofarma Tbk (ISX:INAF) has a Total Inventories of Rp65,552 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for PT Indofarma Tbk and its competitors.
Is PT Indofarma Tbk's Total Inventories too high?
PT Indofarma Tbk's current Total Inventories is Rp65,552 Mil. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Total Inventories compare to ZTS and VTRS?
PT Indofarma Tbk's Total Inventories of Rp65,552 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for PT Indofarma Tbk and its competitors. PT Indofarma Tbk's current Total Inventories is Rp65,552 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Total Inventories of Rp65,552 Mil. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Total Inventories is Rp65,552 Mil. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Total Inventories is Rp65,552 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued.
The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.
Key valuation signals for ISX:INAF:
Total Inventories: Rp65,552 Mil
GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score
Get the complete analysis for ISX:INAF
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:INAF has been successfully added to your 
